Top Markets
Coin of the day
PCL, Inc. PCL, Inc.

PCL, Inc.

241820
주식 순위 #31786
PCL, Inc. specializes in providing sophisticated multiplex in vitro diagnostic... PCL, Inc. specializes in providing sophisticated multiplex in vitro diagnostic (IVD) solutions, encompassing both diagnostic products and specialized platform services. The company's primary offerings include comprehensive multiplex kits designed to detect antibodies to Human Immunodeficiency Virus (HIV) types 1 and 2, Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), and Human T-lymphotropic Virus (HTLV) types 1 and 2. These kits also identify specific antigens such as HIV p24, HCV core, and HBV surface markers in human serum or plasma samples. In addition to these, PCL markets Ai, a rapid diagnostic test kit capable of typing influenza A and B strains; Cancer6, a screening kit for multiple tumor biomarkers; and the sciLINER LATERAL FLOW DISPENSER, an advanced dispensing device for membrane materials featuring active visual drop volume control. Beyond its product portfolio, PCL offers valuable platform services. These include a sol-gel spotting service, which immobilizes client-specified materials using the proprietary SolB reagent, and an SG ID service, providing customers with identified molecules of interest securely immobilized within the SolB reagent. PCL, Inc. is headquartered in Seoul, South Korea.
주가
$0.21291741
마지막 동기화: 2025-04-18
시가총액
$12.07M
변동 (1일)
0.00%
변동 (1년)
0.00%
국가
KR
거래 PCL, Inc. (241820)

카테고리

PCL, Inc. (241820)의 수익
Sep 2025 기준 수익 TTM: $-33.90M
PCL, Inc.의 최신 재무 보고서에 따르면 회사의 현재 수익은 $-33.90M입니다. 2023년에 회사는 $-15.73M의 수익을 올렸으며 이는 2022년의 수익 $-3.18M과 감소입니다. 이 페이지에 표시된 수익은 이자 및 세금 공제 전 수익으로, 즉 EBIT입니다.
PCL, Inc.의 수익 기록 (2015 ~ 2026)
연말 수익
연도 수익 변화
2026 (TTM) $-33.90M -5.68%
2024 $-35.94M 128.48%
2023 $-15.73M 394.91%
2022 $-3.18M -88.07%
2021 $-26.64M -248.25%
2020 $17.97M -360.49%
2019 $-6.90M 33.10%
2018 $-5.18M 42.76%
2017 $-3.63M 87.03%
2016 $-1.94M 22.38%
2015 $-1.59M 0.00%
유사 기업 또는 경쟁사의 수익
회사 수익 수익 차이 국가
$7.51B -22,254.56%
US
$5.15B -15,284.62%
US
$5.56B -16,508.71%
IE
$3.86B -11,488.46%
US
$1.42B -4,281.37%
US